Nicotine replacement therapy is over-promoted since most ex-smokers quit unassisted

Health authorities should emphasize the positive message that the most successful method used by most ex-smokers is unassisted cessation, despite the promotion of cessation drugs by pharmaceutical companies and many tobacco control advocates.The dominant messages about smoking cessation contained in most tobacco control campaigns, which emphasize that serious attempts at quitting smoking must be pharmacologically or professionally mediated, are critiqued in an essay in this week's PLoS Medicine by Simon Chapman and Ross MacKenzie from the School of Public Health at the University of Sydney, Australia. This overemphasis on quit methods like nicotine replacement therapy (NRT) has led to the "medicalisation of smoking cessation," despite good evidence that the most successful method used by most ex-smokers is quitting "cold turkey" or reducing-then-quitting. Reviewing 511 studies published in 2007 and 2 008 the authors report that studies repeatedly show that two-thirds to three-quarters of ex-smokers stop unaided and most ex-smokers report that cessation was less difficult than expected.

The medicalisation of smoking cessation is fuelled by the extent and influence of pharmaceutical support for cessation intervention studies, say the authors. They cite a recent review of randomized controlled trials of nicotine replacement therapy (NRT) that found that 51% of industry-funded trials reported significant cessation effects, while only 22% of non-industry trials did. Many assisted cessation studies--but few if any unassisted cessation studies--involve researchers who declare support from a pharmaceutical company manufacturing cessation products.

The authors conclude that "public sector communicators should be encouraged to redress the overwhelming dominance of assisted cessation in public awareness, so that some balance can restored in smokers' minds regarding the contribution that assisted and unassisted smoking cessation approaches can make to helping them quit smoking."

###

Funding: National Health and Medical Research Council (Australia) Project Grant 2006󈝵 #401558.The funders had no role in the decision to submit this manuscript or in its preparation.

Competing Interests: SC was a member of the Australian Smoking Cessation Consortium that received research funding from GlaxoSmithKline in 2001�.

CONTACT:
Simon Chapman
University of Sydney
School of Public Health
University of Sydney, NSW 2006
Australia
+61-438 340304
simon.chapman@sydney.edu.au

Please call Dr Chapman between 7am and 9pm Eastern Australian Summer Time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.